^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imfinzi (durvalumab)

    i
    Other names: MEDI4736, MEDI-4736, MEDI 4736
    Company:
    AstraZeneca
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    1d
    IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov)
    P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201
    1d
    PulmoPrint: In-vivo Fluorescence Molecular Bronchoscopy of Dur-valumab-680LT in Patients With Unresectable Stage III NSCLC After Chemoradiation (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University Medical Center Groningen
    New P2 trial
    |
    Imfinzi (durvalumab)
    1d
    CHORUS: A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • Ilaris (canakinumab)
    2d
    REVIVE: A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • Libtayo (cemiplimab-rwlc)
    2d
    Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=78, Recruiting, City of Hope Medical Center | Active, not recruiting --> Recruiting | N=38 --> 78
    Enrollment open • Enrollment change
    |
    Imfinzi (durvalumab) • lenalidomide
    3d
    Proof-of-principle 4-marker spatial profiling reveals distinct, location-independent immune clusters in biliary tract cancers. (PubMed, Pathol Oncol Res)
    Despite advances with durvalumab plus chemotherapy, prognosis remains poor. However, among patients treated with adjuvant cisplatin/gemcitabine alone, lower CD20/CD8 fractions and higher CD163 abundance at baseline were associated with improved survival. Spatial immune profiling revealed distinct BTC immune architectures at the invasive margin, with different possible impact on survival, thus warranting further characterization and validation in larger cohorts.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    3d
    Real-world outcomes of consolidative durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer: the prognostic role of clinical frailty in the post-PACIFIC era. (PubMed, Transl Lung Cancer Res)
    In this real-world cohort, consolidative durvalumab was independently associated with improved OS, including in patients with PD-L1 expression ≥1%. The absence of an independent PFS association underscores the complexity of survival interpretation in heterogeneous clinical populations.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab)
    3d
    A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov)
    P1/2, N=383, Active, not recruiting, MedImmune LLC | Trial completion date: Sep 2025 --> Jul 2027
    Trial completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • monalizumab (IPH2201)
    3d
    Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma. (PubMed, JTO Clin Res Rep)
    This single-arm phase II trial enrolled patients with EPSCC to investigate the activity of first-line durvalumab (1500 mg every 3 wk) and 4 to 6 cycles of chemotherapy (either cisplatin or carboplatin) with etoposide, followed by maintenance durvalumab 1500 mg every 4 weeks until disease progression. This study reveals that durvalumab plus chemotherapy is safe and has some activity in rare small cell cancers outside the lung, but benefits are modest and short lived. Current treatment remains largely chemotherapy based, highlighting the urgent need for larger, collaborative research efforts to find more effective options for these patients.
    P2 data • Journal • Tumor mutational burden • PD(L)-1 Biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1)
    |
    TP53 mutation
    |
    TruSight Oncology 500 Assay • TruSight Tumor 170 Assay
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • etoposide IV
    4d
    A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2 (2025-521608-23-00)
    P1/2, N=56, Not yet recruiting, IRCCS Istituto Nazionale Tumori Fondazione Pascale
    New P1/2 trial
    |
    Imfinzi (durvalumab) • Lenvima (lenvatinib) • Imjudo (tremelimumab-actl)
    4d
    A clinical trial of MK-1084 and durvalumab in people with non-small cell lung cancer (MK-1084-015) (2025-522038-29-00)
    P2/3, N=27, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Imfinzi (durvalumab) • calderasib (MK-1084)
    7d
    DURANCE: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (clinicaltrials.gov)
    P1/2, N=52, Recruiting, University College, London | Trial completion date: May 2029 --> Sep 2032 | Trial primary completion date: May 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • S-588210